Diversified science and technology company Danaher (NYSE: DHR) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to $5.95 billion. Its non-GAAP profit of $2.06 per share was 6.4% above analysts’ consensus estimates.
Is now the time to buy Danaher? Find out by accessing our full research report, it’s free.
Danaher (DHR) Q1 CY2026 Highlights:
- Revenue: $5.95 billion vs analyst estimates of $6.00 billion (3.7% year-on-year growth, 0.8% miss)
- Adjusted EPS: $2.06 vs analyst estimates of $1.94 (6.4% beat)
- Adjusted Operating Income: $1.34 billion vs analyst estimates of $1.71 billion (22.6% margin, 21.3% miss)
- Management slightly raised its full-year Adjusted EPS guidance to $8.45 at the midpoint
- Operating Margin: 22.6%, in line with the same quarter last year
- Free Cash Flow Margin: 18.2%, similar to the same quarter last year
- Organic Revenue was flat year on year (miss)
- Market Capitalization: $138.4 billion
Company Overview
Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE: DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, Danaher struggled to consistently increase demand as its $24.78 billion of sales for the trailing 12 months was close to its revenue five years ago. This wasn’t a great result and is a sign of lacking business quality.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Danaher’s annualized revenue growth of 2.2% over the last two years is above its five-year trend, which is encouraging. 
Danaher also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Danaher’s organic revenue averaged 1.1% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. 
This quarter, Danaher’s revenue grew by 3.7% year on year to $5.95 billion, falling short of Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to grow 4.6% over the next 12 months. While this projection indicates its newer products and services will catalyze better top-line performance, it is still below average for the sector.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Danaher has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 30.8%.
Analyzing the trend in its profitability, Danaher’s adjusted operating margin decreased by 10.6 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.7 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
In Q1, Danaher generated an adjusted operating margin profit margin of 22.6%, down 7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Danaher’s EPS was flat over the last five years, just like its revenue. This performance was underwhelming across the board.
In Q1, Danaher reported adjusted EPS of $2.06, up from $1.88 in the same quarter last year. This print beat analysts’ estimates by 6.5%. Over the next 12 months, Wall Street expects Danaher’s full-year EPS of $7.98 to grow 7.2%.
Key Takeaways from Danaher’s Q1 Results
It was good to see Danaher beat analysts’ EPS expectations this quarter. We were also happy its full-year EPS guidance narrowly outperformed Wall Street’s estimates. On the other hand, its revenue slightly missed and its organic revenue fell slightly short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock remained flat at $195.75 immediately after reporting.
Should you buy the stock or not? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
